GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acorda Therapeutics Inc (FRA:CDG) » Definitions » Institutional Ownership

Acorda Therapeutics (FRA:CDG) Institutional Ownership : 1.59% (As of Jun. 08, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Acorda Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Acorda Therapeutics's institutional ownership is 1.59%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Acorda Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Acorda Therapeutics's Float Percentage Of Total Shares Outstanding is 99.48%.


Acorda Therapeutics Institutional Ownership Historical Data

The historical data trend for Acorda Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acorda Therapeutics Institutional Ownership Chart

Acorda Therapeutics Historical Data

The historical data trend for Acorda Therapeutics can be seen below:

2023-04-30 2023-05-31 2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31
Institutional Ownership 1.10 1.57 1.54 1.58 1.58 1.58 1.58 1.58 1.59 1.59

Acorda Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Acorda Therapeutics (FRA:CDG) Business Description

Traded in Other Exchanges
Address
2 Blue Hill Plaza, 3rd Floor, Pearl River, New York, NY, USA, 10965
Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.

Acorda Therapeutics (FRA:CDG) Headlines

No Headlines